AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Imjudo (tremelimumab) — Worldwide YoY CER by Quarter
Imjudo (tremelimumab) — Worldwide YoY CER (%) (%)
AstraZeneca Imjudo (tremelimumab) — Worldwide YoY CER: -7.0% in Q2 2026, down 25.0 pts from a year earlier. That is the lowest of the 10 quarters on record here.
Where the Q2 2026 figure comes from
“|| Imjudo | | 83 | | ( 7 ) | | ( 7 ) | | 51 | | ( 11 ) | | 7 | | ( 3 ) | | ( 3 ) | | 14 | | 25 | | 20 | | 11 | | ( 21 ) | | ( 16 )”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imjudo (tremelimumab) — Worldwide YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -7.0% | -25.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -7.0% | -40.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 26.0% | -2.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 14.0% | -8.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 18.0% | -1.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 33.0% | -37.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 28.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 22.0% | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 19.0% | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 70.0% | – | Form 6-K FY2024Q1 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Imjudo (tremelimumab) — Worldwide YoY CER (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imjudo-world-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.